Meininger D P, Hunter M J, Komives E A
Department of Chemistry and Biochemistry, University of California-San Diego, La Jolla 92093-0601, USA.
Protein Sci. 1995 Sep;4(9):1683-95. doi: 10.1002/pro.5560040904.
The fourth EGF-like domain of thrombomodulin (TM4), residues E346-F389 in the TM sequence, has been synthesized. Refolding of the synthetic product under redox conditions gave a single major product. The disulfide bonding pattern of the folded, oxidized domain was (1-3, 2-4, 5-6), which is the same as that found in EGF protein. TM4 was tested for TM anticoagulant activity because deletion and substitution mutagenesis experiments have shown that the fourth EGF-like domain of TM is essential for TM cofactor activity. TM4 showed no TM-like activity in two assay systems, both for inhibition of fibrin clot formation, and for cofactor activity in thrombin activation of protein C. A preliminary structure of TM4 was determined by 2D 1H NMR from 519 NOE-derived distance constraints. Distance geometry calculations yielded a single convergent structure. The structure resembles the structure of EGF and other known EGF-like domains but has some key differences. The central two-stranded beta-sheet is conserved despite the differences in the number of amino acids in the loops. The C-terminal loop formed by the disulfide bond between C372 and C386 in TM4 is five amino acids longer than the analogous loop between C33 and C42 of EGF protein. This loop appears to have a different fold in TM4 than in EGF protein. The loop forms the two outside strands of a broken, irregular tri-stranded beta-sheet, and amino acids H384-F389 lie between the two strands forming the middle strand of the sheet. Thus, although the C-terminus of EGF protein forms one of the outside strands of a tri-stranded antiparallel sheet, the C-terminus of TM4 forms the inside strand of an irregular tri-stranded parallel-anti-parallel sheet. The residues D349, E357, and E374, which were shown to be critical for cofactor activity by alanine scanning mutagenesis, all lie in a patch near the C-terminal loop, and are solvent accessible. The other critical residues, Y358 and F376, are largely buried and appear to play essential structural rather than functional roles.
已合成血栓调节蛋白的第四个表皮生长因子样结构域(TM4),即TM序列中第E346 - F389位的残基。在氧化还原条件下对合成产物进行重折叠得到单一主要产物。折叠后的氧化结构域的二硫键模式为(1-3、2-4、5-6),与表皮生长因子(EGF)蛋白中的模式相同。由于缺失和取代诱变实验表明TM的第四个表皮生长因子样结构域对TM辅因子活性至关重要,因此对TM4进行了TM抗凝活性测试。在两个检测系统中,TM4在抑制纤维蛋白凝块形成以及在凝血酶激活蛋白C的辅因子活性方面均未表现出类似TM的活性。通过二维¹H NMR从519个源自核Overhauser效应(NOE)的距离限制确定了TM4的初步结构。距离几何计算得出单一收敛结构。该结构类似于EGF和其他已知的表皮生长因子样结构域,但存在一些关键差异。尽管环中氨基酸数量不同,但中央的双链β-折叠是保守的。TM4中由C372和C386之间的二硫键形成的C末端环比EGF蛋白中C33和C42之间的类似环长五个氨基酸。该环在TM4中的折叠似乎与EGF蛋白中的不同。该环形成一个断裂的、不规则的三链β-折叠的两条外侧链,氨基酸H384 - F389位于形成该折叠中间链的两条链之间。因此,尽管EGF蛋白的C末端形成三链反平行β-折叠的一条外侧链,但TM4的C末端形成不规则三链平行-反平行β-折叠的内侧链。丙氨酸扫描诱变显示对辅因子活性至关重要的残基D349、E357和E374均位于靠近C末端环的一个区域,且可接触溶剂。其他关键残基Y358和F376大多被掩埋,似乎发挥重要的结构而非功能作用。